PMID- 23567202
OWN - NLM
STAT- MEDLINE
DCOM- 20131226
LR  - 20130528
IS  - 1873-5177 (Electronic)
IS  - 0091-3057 (Linking)
VI  - 106
DP  - 2013 May
TI  - Effects of TrkB agonist 7,8-dihydroxyflavone on sensory gating deficits in mice 
      after administration of methamphetamine.
PG  - 124-7
LID - S0091-3057(13)00082-8 [pii]
LID - 10.1016/j.pbb.2013.03.016 [doi]
AB  - Several lines of evidence suggest that the brain-derived neurotrophic factor 
      (BDNF)-tropomyosin-related kinase B (TrkB) signaling pathway plays a role in 
      behavioral abnormalities observed after administration of psychostimulants, such 
      as methamphetamine (METH). This study was undertaken to examine whether the 
      potent TrkB agonist, 7,8-dihydroxyflavone (7,8-DHF) could improve prepulse 
      inhibition (PPI) deficits in mice seen after a single dose of METH. Treatment 
      with 7,8-DHF (3.0, 10 or 30 mg/kg) improved PPI deficits in mice associated with 
      exposure to METH (3.0 mg/kg), in a dose dependent manner. Furthermore, 
      co-administration of ANA-12 (0.5 mg/kg), a TrkB antagonist, significantly blocked 
      the effects of 7,8-DHF (30 mg/kg) on METH-induced PPI deficits. In contrast, 
      administration of 5,7-dihydroxyflavone (5,7-DHF: 30 mg/kg), an inactive TrkB 
      ligand, did not affect METH-induced PPI deficits in mice. An in vivo 
      microdialysis study in conscious mice showed that 7,8-DHF (30 mg/kg) 
      significantly attenuated increased dopamine release in the striatum, after METH 
      administration (3 mg/kg). This study suggests that 7,8-DHF can improve PPI 
      deficits in these mice, through the inhibition of METH-induced dopamine release. 
      Therefore, it is likely that TrkB agonists, such as 7,8-DHF, may constitute a 
      novel class of therapeutic drugs for neuropsychiatric diseases such as METH-use 
      disorder and schizophrenia.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Ren, Qian
AU  - Ren Q
AD  - Division of Clinical Neuroscience, Chiba University Center for Forensic Mental 
      Health, Chiba, Japan.
FAU - Zhang, Ji-Chun
AU  - Zhang JC
FAU - Fujita, Yuko
AU  - Fujita Y
FAU - Ma, Min
AU  - Ma M
FAU - Wu, Jin
AU  - Wu J
FAU - Hashimoto, Kenji
AU  - Hashimoto K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130406
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (6,7-dihydroxyflavone)
RN  - 0 (Flavones)
RN  - 44RAL3456C (Methamphetamine)
RN  - EC 2.7.10.1 (Receptor, trkB)
SB  - IM
MH  - Animals
MH  - Flavones/*pharmacology
MH  - Ion Channel Gating/*drug effects
MH  - Male
MH  - Methamphetamine/administration & dosage/*toxicity
MH  - Mice
MH  - Microdialysis
MH  - Receptor, trkB/*antagonists & inhibitors
EDAT- 2013/04/10 06:00
MHDA- 2013/12/27 06:00
CRDT- 2013/04/10 06:00
PHST- 2012/12/27 00:00 [received]
PHST- 2013/03/21 00:00 [revised]
PHST- 2013/03/29 00:00 [accepted]
PHST- 2013/04/10 06:00 [entrez]
PHST- 2013/04/10 06:00 [pubmed]
PHST- 2013/12/27 06:00 [medline]
AID - S0091-3057(13)00082-8 [pii]
AID - 10.1016/j.pbb.2013.03.016 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 2013 May;106:124-7. doi: 10.1016/j.pbb.2013.03.016. Epub 
      2013 Apr 6.